Phase II: Adaptive De-escalation of Radiation Therapy Dose In Favorable Risk HPV-Positive Oropharyngeal Carcinoma (ART)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Head And Neck Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have pathologically (histological or cytological) proven diagnosis of squamous cell carcinoma of the oropharynx, which includes the site tonsil, base of the tongue, soft palate, or posterior oropharyngeal wall.

     

    2.  Patients must have tissue that is positive for p16 by immunohistochemical staining

     

    3.  Patient must have an involved lymph node.


You may not be eligible for this study if the following are true:

  • 1.  Patients with cancers considered to be from an oral cavity site (oral tongue, floor of mouth, alveolar ridge, buccal or lip), or the nasopharynx, hypopharyhnx, or larynx (even if p16 positive)

     

    2.  Patients with carcinoma of the neck unknown primary site origin (even if p16 positive)

     

    3.  Prior systemic chemotherapy for the study cancer; prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy

     

    4.  Inability to tolerate cisplatin

     

    5.  Pregnancy or lactation




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.